Workflow
NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System
GlobeNewswire News Room·2025-06-23 12:30

Core Insights - NeuroOne Medical Technologies Corporation announced that Clara, an early patient treated with the OneRF® Ablation System, has surpassed one year seizure-free, significantly improving her quality of life [1][2]. Company Overview - NeuroOne is focused on developing and commercializing minimally invasive and high-definition solutions for various neurological disorders, including epilepsy, Parkinson's disease, and chronic pain [5]. - The OneRF® Ablation System is the first FDA 510(k)-cleared device that utilizes the same sEEG electrode for both diagnostic and therapeutic applications, allowing for monitoring, mapping, and ablation at the bedside [3]. Product Performance - The OneRF® Ablation System has demonstrated seizure reduction or freedom for most patients who have undergone the procedure [3]. - Clara's experience highlights the effectiveness of the OneRF® platform, as she transitioned from experiencing multiple seizures daily to being completely seizure-free [4]. Future Developments - The company plans to leverage the OneRF® technology for additional applications, including the OneRF® Trigeminal Nerve Ablation System aimed at treating facial pain, with a 510(k) submission filed to the FDA in April 2025 [4].